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ABSTRACT
Aims To evaluate the utility of coffee-related genetic variants as proxies for coffee consumption in Mendelian randomi-
zation studies, by examining their association with non-alcoholic beverage consumption (including subtypes of coffee and
tea) and a range of socio-demographic and life-style factors.Design Observational study of the association of genetic risk
scores for coffee consumption with different types of non-alcoholic beverage consumption. Setting UK general popula-
tion. Participants Individuals of European ancestry aged 40–73 years from the UK Biobank between 2006 and 2010
(n = 114316).Measurements Genetic risk scores were constructed using two, four and eight independent single nu-
cleotide polymorphisms (SNPs) identiﬁed in genome-wide association studies (GWAS) of coffee consumption. Drinks were
self-reported in a baseline questionnaire (all participants) and in detailed 24 dietary recall questionnaires in a subset
(n = 48692). Findings Genetic risk scores explained up to 0.38, 0.19 and 0.76% of the variance in coffee, tea and com-
bined coffee and tea consumption, respectively. Genetic risk scores demonstrated positive associations with both caffein-
ated and decaffeinated coffee and tea consumption, and with most subtypes of coffee consumption, but only with
standard tea consumption. There was no clear evidence for positive associations with most other non-alcoholic beverages,
but higher genetic risk for coffee consumption was associated with lower daily water consumption. The genetic risk scores
were associated with increased alcohol consumption, but not consistently with other socio-demographic and life-style fac-
tors. Conclusions Coffee-related genetic risk scores could be used as instruments for combined coffee and tea consump-
tion in Mendelian randomization studies. However, associations observed with alcohol consumption require further
investigation to determine whether these are due to causal effects of coffee and tea consumption or biological pleiotropy.
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INTRODUCTION
Genome-wide association studies (GWAS) have identiﬁed
eight independent loci that are associated with coffee con-
sumption at the genome-wide signiﬁcance level [1–3]. The
two most strongly associated loci identiﬁed to date are in or
near genes which are involved in caffeine metabolism,
namely the cytochrome P450 1A1 and 1A2 (CYP1A1/2)
gene region and aryl-hydrocarbon receptor gene (AHR)
[4]. CYP1A2 is the enzyme responsible primarily for me-
tabolizing caffeine and AHR affects CYP1A2 activity [4].
It is likely that these variants affect coffee consumption
through altering rate of caffeine metabolism; there is
evidence that the coffee consumption-increasing alleles of
these single nucleotide polymorphisms (SNPs) decrease
blood caffeine levels [5,6]. Of note, ﬁve of the six additional
loci (or close proxies, in or near the following genes: GCKR,
ABCG2, MLXIPL, BDNF, EFCAB5) have also been identi-
ﬁed in GWAS of other phenotypes, such as bodymass index
and smoking initiation [3,7,8]. Combining variants to-
gether in an allele score increases the amount of variance
in coffee consumption explained [9,10]. However, there is
also evidence that coffee-related SNPs and genetic risk
scores associate more broadly with caffeinated beverage
consumption [10] and with decaffeinated coffee intake
[3]. Better characterization of the coffee and caffeine
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phenotypes that this genetic risk score capture is important
for interpreting the results of analyses that use these as
proxies or markers of coffee exposure.
One important method for which coffee genetic risk
score may prove useful is Mendelian randomization, which
uses genetic variants as proxies for measured exposures to
strengthen causal inference [11]. Unlike measured coffee
consumption genetic variants should, in theory, be inde-
pendent of confounders that may distort relationships be-
tween coffee consumption and should not be affected by
reverse causality (see Fig. 1). To be suitable instruments
for Mendelian randomization analyses, genetic risk scores
for coffee or caffeine consumption should (1) be associated
robustly with the exposure of interest, (2) not be associated
with potential confounding factors of the exposure–
outcome relationship and (3) be associated with the out-
come only through the exposure of interest (the exclusion
restriction assumption) [12]. Biological pleiotropy (i.e. a
genetic variant inﬂuencing more than one phenotypic
trait) can often violate the third assumption in Mendelian
randomization studies (although methods for accounting
for potential bias due to pleiotropy [13], such as MR Egger
[14] have been developed). This can be particularly prob-
lematic when exposures are complex behavioural traits
such as substance use, given the numerous biological path-
ways involved and the likelihood that genetic variation in
these pathways will have multiple downstream effects.
Given that caffeine is themostwidely used psychoactive
substance in the world [15], and that consumption of cof-
fee and tea is associated with numerous health outcomes,
including cardiovascular disease, diabetes, depression and
mortality [16–19], the use of these genetic risk scores is
likely to becomemorewidespread. There is considerable in-
terest in the potential effects of coffee, tea and caffeine con-
sumption on health; to date, coffee-related variants have
been used in Mendelian randomization analyses as instru-
ments for coffee consumption to investigate associations
with diabetes [20], cardiovascular risk factors, depression,
childhood cognition andAlzheimer’s disease [21] and pros-
tate cancer [22]. More detailed assessment of how genetic
risk scores relate to the exposure of interest (i.e. coffee) and
how speciﬁc they are as instruments for this exposure is
necessary for interpreting the results of these studies cor-
rectly and understanding the potential limitations of Men-
delian randomization for investigating the causal effects of
these traits.
We conducted the analysis in 114316 individuals from
the UK Biobank study, including a subset of 48692 individ-
uals with 2-hour dietary recall data, with the aims of deter-
mining the associations of coffee-related genetic risk scores
with: (1) non-alcoholic beverage consumption (including
subtypes of coffee and tea) and (2) socio-demographic
and life-style factors. These analyses extend previously
published work conducted in UK Biobank, which presented
directions of effect and P-values of these SNPs with coffee
and tea intake, but did not investigate associations with
subtypes of coffee and tea or other beverages [6].
METHODS
Design
We calculated polygenic risk scores from a previously pub-
lished genome-wide analysis of coffee consumption and
tested associations of these with self-reported dietary, life-
style and socio-demographic data in the UK Biobank.
Study population
The UK Biobank (www.ukbiobank.ac.uk) recruited more
than 500000 men and women (aged 40–73 years)
Figure 1 Diagram of Mendelian randomization approach. In Mendelian randomization, genetic variants for coffee consumption are used as instru-
ments for measured coffee consumption to assess if relationships between coffee consumption and disease are likely to be causal. Unlike measured
coffee consumption, under the assumptions of Mendelian randomization, genetic variants that inﬂuence coffee consumption should not be associated
with potential confounding factors and will not be affected by the disease outcome (no reverse causality)
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between 2006 and 2010 [23]. Participants attended one of
the 22 assessment centres in England,Wales and Scotland,
where they provided information on demographic, life-
style factors and medical history through interviews and
questionnaires and had physical measurements and blood,
urine and saliva samples taken. The full protocol for the
study is available online: www.ukbiobank.ac.uk/wp-con-
tent/uploads/2011/11/UK-Biobank-Protocol.pdf. The UK
Biobank study was approved by the North West Multi-
Centre Research Ethics Committee and all participants pro-
vided written informed consent to participate in the UK
Biobank study.
Genetic risk scores
We created genetic risk scores for caffeine consumption
using eight SNPs from eight independent loci that reached
genome-wide signiﬁcance, with coffee consumption in the
trans-ethnic meta-analysis in the Coffee and Caffeine Ge-
netics Consortium (CCGC) (rs4410790, rs2470893,
rs1260326, rs1481012, rs7800944, rs9902453,
rs17685, rs6265) [3]. We also created a genetic risk score
using only variants in or near the strongest two loci, AHR
(rs4410790) and CYP1A1/2 (rs2470893), which have
been identiﬁed in multiple GWAS studies of coffee con-
sumption [1,2] and a score with four SNPs from loci that
reached genome-wide signiﬁcance in the European discov-
ery sample and were replicated in the European replication
sample (rs4410790, rs2470893, rs7800944, rs17685).
Full details of these SNPs are provided in Supporting infor-
mation, Table S1. Unweighted risk scores were created by
adding together the number of coffee consumption-
increasing alleles. Weighted risk scores were created by
multiplying each coffee consumption-increasing allele by
the magnitude of its association with coffee consumption
in individuals of European ancestry in the discovery sample
of the CCGC genome-wide association study [3] (see
Supporting information, Table S1). The UK Biobank sam-
ple was not part of the CCGC GWAS sample.
Tea, coffee and other beverage consumption
Information about usual intake of tea and coffee were
assessed as part of the baseline questionnaire, which
was administered to all participants during their visit
to the initial assessment centre. All UK Biobank partici-
pants were asked how many glasses of water they drank
each day. For each type of drink, answers were provided
on a continuous scale and we excluded individuals
reporting drinking > 25 cups/glasses a day. Information
on tea, coffee and other non-alcoholic beverage con-
sumption was also obtained for a subset of participants
on up to ﬁve occasions from a validated 24-hour diet re-
call [24]. Full details of the questions asked, the coding
of drink consumption and the coding of caffeinated
and decaffeinated coffee and tea consumption are pro-
vided in the Supporting information.
Socio-demographic and life-style factors
Information on education, socio-economic deprivation, al-
cohol consumption and income was collected at baseline.
See Supporting information for details.
Statistical analysis
Analyses were conducted in Stata version 14.2. Associa-
tions between genetic risk scores and consumption of each
type of beverage were assessed using linear regression,
adjusting for age (as a continuous variable), sex and 15 ge-
netic principal components. Robust standard errors were
calculated to account for non-normality of residuals.
Weighted risk scores were converted to Z-scores, so associ-
ations are per standard deviation (SD) increase. Associa-
tions for unweighted risk scores are per additional coffee
consumption-increasing allele. Primary analyses in the full
UK Biobank sample were conducted in all individuals (con-
sumers and non-consumers). Analyses in the subset with
dietary datawere restricted to consumers of each beverage,
as many of the beverages were consumed by only a small
proportion of the sample. We also tested for associations
with any versus no tea and coffee consumption in the full
sample using logistic regression.Where evidence for associ-
ations with beverages other than coffee or tea was found,
we investigated whether associations might be due to
causal effects of coffee or tea consumption by performing
inverse variance-weighted Mendelian randomization and
methods which are more robust to the effects of pleiotropy:
median-weighted regression [25] and MR Egger [14]. A
more detailed explanation of these analyses is provided in
the Supporting information.
Sensitivity analyses
Smoking is known to increase caffeine metabolism
through induction of CYP1A2 [26], so we performed a
sensitivity analysis in the full sample stratiﬁed by
smoking status (never, former and current). As the ini-
tial GWAS release of the UK Biobank contains data from
a nested case–control study, participants were selected
on the basis of lung function and smoking status (UK
BiLEVE) [27]; we also repeated analyses excluding these
individuals.
RESULTS
Description of study population
A total of 114316 unrelated individuals of European an-
cestry were included in the analysis of coffee and tea
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captured at the initial UK Biobank assessment centre (see
Supporting information, Fig. S1). Dietary recall data were
available for a subset of 48692 of these individuals
(Table 1). Prevalence of tea and coffee consumption was
high (85% of individuals were tea consumers and 78% cof-
fee consumers in the full sample). Coffee and tea intake
were correlated negatively (r = 0.33 in all individuals
and r = 0.17 in individuals consuming both tea and cof-
fee; P-values < 0.001).
Variance explained in coffee and tea consumption by
genetic risk score
In the ﬁrst release of the UK Biobank sample with genetic
data, there was evidence that each of the SNPs apart from
rs6265 were associated with coffee consumption (either in
the full sample or only in coffee consumers) in the same di-
rection as described previously (Supporting information,
Fig. S2) [3] .The two SNP, four SNP and eight SNP genetic
risk scores were associated with coffee and tea intake (see
Table 2). The risk scores explained up to 0.38% of the vari-
ance incoffeeconsumedperday,upto0.19%of thevariance
in tea consumed per day and up to 0.76% of the variance in
tea and coffee combined. The weighted eight SNP score ex-
plained the highest proportion of the variance for both tea
and coffee (Table 2). However, the majority of this variance
was explained by the two strongest SNPs (rs4410790 and
rs2470893). Variance explained by the additional six SNPs
alone is shown in Supporting information, Table S2. The
eightSNPgenetic risk score explainedavery similar amount
of variance to the four SNP genetic risk score.
There was evidence that the caffeine genetic risk scores
were associated with higher odds of drinking any coffee
compared to no coffee [odds ratio (OR) per SD increase in
eight SNP-weighted genetic risk score = 1.06, 95% conﬁ-
dence interval (CI) = 1.05, 1.08]. However, there was no
clear evidence that the genetic risk scores were associated
with consuming either any tea or any tea or coffee com-
bined (Supporting information, Table S3). Associations be-
tween the genetic risk scores and coffee and tea combined
were similar at low and medium levels of coffee/tea con-
sumption. In high consumers (> 10 cups per day) magni-
tudes of effect were lower, but estimates were imprecise
(Supporting information, Table S4).
Associations of genetic risk score with coffee, tea and other
beverage consumption
In analyses restricted to consumers of each type of drink, in
the full sample each additional coffee consumption-
increasing allele of the two SNP genetic risk score was asso-
ciated with a 0.12 increase in the number of cups of coffee
consumed per day (95% CI = 0.10, 0.13), a 0.14 increase
in the number of cups of tea consumed per day (95%
CI = 0.13, 0.16) and a 0.24 increase in the number of cups
of tea and coffee combined (95% CI = 0.22, 0.26). We ob-
served a negative association with water consumption;
each additional coffee consumption-increasing allele was
associated with consuming 0.06 fewer glasses of water
per day (95% CI = –0.07, 0.04).
Similar patterns were observed in the subset of individ-
uals with dietary recall data; the two SNP-unweighted ge-
netic risk score was associated positively with most types of
coffee consumption (Fig. 2). Each additional caffeine
consumption-increasing allele was associated with higher
consumption of instant, ﬁlter, latte, decaffeinated and total
coffee. For cappuccino and other coffee, point estimates
were in the positive direction but there was little statistical
evidence for associations. The genetic risk score was also
associated with increased standard tea but not with
rooibos, green tea or herbal tea. As observed in the full
sample, the genetic risk score was associated negatively
with water consumption. The genetic risk score was asso-
ciated positively with combined coffee and tea consump-
tion (0.18 additional portions consumed per additional
coffee consumption-increasing allele, 95% CI = 0.16,
0.19), but negatively with non-coffee and tea consumption
(0.07 fewer portions consumed per additional coffee
consumption-increasing allele, 95% CI = –0.09, 0.05).
Results using the four and eight SNP-weighted genetic risk
score were similar (Supporting information, Figs S3 and
S4). There was no clear evidence that the genetic risk score
Table 1 Description of study samples.
Full sample
(n = 114 316)
Subset with dietary
recall data
(n = 48 692)
Male: n (%) 54024 47.26 22789 46.80
Age: mean (SD) 56.9 7.92 56.49 7.79
Education
None 20615 18.20 4559 9.40
NVQ/CSE/A-levels 40898 36.10 16578 34.17
Degree/professional 51770 45.70 27377 56.43
Any tea consumption 96765 84.65 41324 84.98
Tea (cups per day) 3 1,5 3 1,5
Any coffee consumption 90005 78.73 39298 80.77
Coffee (cups per day) 2 0.5,3 2 0.5,3
Smoking
Never 61179 53.65 27389 56.35
Former 39006 34.21 16848 34.66
Current 13844 12.14 4371 8.99
Questionnaires completed: n (%)
1 19093 39.21
2 11160 22.92
3 9895 20.32
4 7198 14.78
5 1346 2.76
SD = standard deviation; NVQ = National Vocational Qualiﬁcation;
CSE = Certiﬁcate of Secondary Education; A-level = Advanced level.
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was associated with speciﬁc consumption of any of the
other non-tea or coffee beverages, apart from suggestive
evidence for increased consumption of ﬂavoured milk and
hot chocolate. However, evidence for these associations
was weaker with the four and eight SNP score.
The two SNP genetic risk score was positively
associated with both caffeinated and decaffeinated tea
and coffee consumption (Fig. 3). Point estimates for
decaffeinated coffee consumption and caffeinated coffee
consumption were similar in the full UK Biobank sample,
but were smaller for decaffeinated coffee consumption
(beta 0.06, 95% CI = 0.03, 0.09) than for caffeinated
consumption (beta 0.09, 95% CI = 0.08, 0.11) in the die-
tary recall sample. For tea consumption, point estimates
were similar for both caffeinated and decaffeinated in the
dietary recall study. Similar patterns were observed for
the eight and four SNP scores (see Supporting informa-
tion, Figs S5 and S6).
Association of genetic risk score with demographic and
life-style factors
To test the second assumption of Mendelian randomization
analysis, we investigated associations between the instru-
ment and potential confounding factors.We found no clear
evidence that the genetic risk scores were associated with
age, education levels, income or level of deprivation
(Table 3). However, therewas evidence for a positive associ-
ation with both frequency of alcohol consumption (OR for
daily versusnon-daily consumption per SD increase in eight
SNP genetic risk score 1.02, 95% CI = 1.01, 1.04) and
weekly alcohol consumption among alcohol consumers.
The two SNP genetic risk score also showed suggestive evi-
dence of being associated with current smoking (OR for
current smoking per coffee consumption-increasing allele
0.98 (95% CI = 0.96, 1.00) and sex (OR for female sex
per coffee consumption-increasing allele 0.99 (95%
CI = 0.97, 1.00), although evidence for these associations
was weaker with the eight SNP genetic risk score. Associa-
tions between genetic risk score and demographic and life-
style factors showed some differences in samples stratiﬁed
into high, medium, low and non-coffee and tea consumers
(Supporting information, Figs S6 and S7).
Sensitivity analyses
There was no strong evidence that associations between
coffee genetic risk score and coffee and tea consumption
differed in never, former or current smokers (Supporting in-
formation, Fig. S8). Restriction of analyses to individuals
not in the UK BiLEVE sample made little difference to the
observed associations (data not shown).
Results from inverse variance-weighted Mendelian ran-
domization analysis, MR Egger and median-weighted re-
gression assessing the association between the eight SNP
genetic risk score and water consumption were highly con-
sistent, providing some support for a negative causal effect
of coffee/tea consumption on total non-coffee and tea con-
sumption and water consumption (see Supporting infor-
mation, Table S5). In contrast, while results from
median-weighted regression supported a potential causal
effect of coffee consumption on alcohol intake, results from
MR Egger analyses suggested potential horizontal or
biological pleiotropy (Supporting information, Table S6).
DISCUSSION
We have conﬁrmed associations of genetic risk score for
coffee consumption using variants identiﬁed in published
GWAS [1–3], with amount of consumption of both coffee
Table 2 Associations of eight and two single nucleotide polymorphism (SNP) genetic risk scores with tea and coffee consumption (cups per
day).
n Unweighted b beta (95% CI) R-squared a Weighted c beta (95% CI) R-squared a
Cups of coffee per day (including decaffeinated)
2 SNP score 114316 0.12 (0.11, 0.13) 0.30% (0.24, 0.35%) 0.11 (0.10, 0.13) 0.30% (0.24, 0.35%)
4 SNP score 113425 0.09 (0.08, 0.10) 0.33% (0.27, 0.39%) 0.13 (0.11, 0.14) 0.36% (0.30,0.42%)
8 SNP score 111469 0.06 (0.06, 0.07) 0.28% (0.23,0.35%) 0.13 (0.12, 0.14) 0.38% (0.32, 0.46%)
Cups of tea per day
2 SNP score 114316 0.12 (0.10, 0.13) 0.16% (0.12, 0.20%) 0.11 (0.10, 0.13) 0.16% (0.12, 0.20%)
4 SNP score 113425 0.09 (0.07, 0.10) 0.16% (0.12, 0.20%) 0.12 (0.11, 0.14) 0.19% (0.15, 0.24%)
8 SNP score 111469 0.06 (0.05, 0.07) 0.13% (0.09, 0.17%) 0.12 (0.11, 0.14) 0.19% (0.14, 0.24%)
Cups of tea and coffee per day
2 SNP score 114316 0.24 (0.22, 0.26) 0.62% (0.53, 0.69%) 0.23 (0.21,0.24) 0.61% (0.53, 0.69%)
4 SNP score 113425 0.18 (0.17, 0.19) 0.65% (0.56, 0.72%) 0.25 (0.23, 0.27) 0.74% (0.66, 0.82%)
8 SNP score 111469 0.12 (0.11, 0.13) 0.54% (0.46, 0.62%) 0.25 (0.24,0.27) 0.76% (0.67, 0.86%)
Analyses include consumers and non-consumers. Eight SNP scores had missing genotype information for 2847 individuals. aCalculated from residuals of risk
score on genetic principal components, regressed on coffee/tea/tea and coffee per day. bAssociations in cups per day per coffee consumption-increasing allele,
adjusted for age, sex and genetic principal components. cAssociations in cups per day per standard deviation (SD) increase in genetic risk score, adjusted for
age, sex and genetic principal components. CI = conﬁdence interval.
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and tea in a large sample of older adults of European ances-
try from the United Kingdom. Using a more detailed mea-
sure of beverage consumption, the 24-hour dietary recall,
we found that the genetic risk score was associated with
most subtypes of coffee consumption, and with black tea
but not herbal tea consumption. These scores were also as-
sociated with decreased consumption of water and total
drinks excluding tea and coffee.
Associations of the genetic risk scores with both coffee
and tea support the use of coffee genetic risk scores as in-
struments for amount of coffee and tea consumed (and
probably caffeine consumption in general) rather than as
speciﬁc markers of coffee consumption. The variance ex-
plained in combined coffee and tea consumption was
0.54–0.76% compared to 0.13–0.38% for coffee or tea
alone. This has been shown previously in a study of women
from the United Kingdom [10] and is unsurprising, given
that the two strongest coffee-related variants in the risk
score (AHR and CYP1A1/2) are in or near genes in caffeine
metabolizing pathways. In addition, the genetic risk scores
inﬂuenced whether individuals were coffee consumers but
not whether they were tea consumers. Lack of association
with any tea consumption may simply reﬂect the wide-
spread consumption of tea in the United Kingdom (85%
in this study), but could also be explained by the lower caf-
feine content of tea compared to coffee.
The effect sizes we observed with coffee consumption
were similar to those observed in previous GWAS of coffee
consumption [2,3]. Our data suggest that using the four
SNP-weighted genetic risk score increases power to detect
associations with caffeinated drink consumption over the
two SNP genetic risk score (weighted or unweighted), but
Figure 2 Associations between the two single nucleotide polymorphism (SNP) genetic risk scores and types of drink in the full sample and dietary
recall subset. Analyses restricted to consumers of each drink, apart from the dietary recall total which included all respondents. Adjusted for age, sex
and principal genetic components
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only by a relatively small amount. Using SNPs from all
eight loci explained a similar amount of variance to the
four SNP score, suggesting that there may be little added
beneﬁt to using the four additional SNPs to improve the
power of analyses in European populations. The fact that
the association of the BDNF SNP rs6265 with coffee con-
sumption did not replicate in UK Biobank (and also did
not replicate in the European sample of the GWAS [3]) sug-
gests that this locus does not associate robustly with coffee
consumption in European samples. The two SNP risk score
may be amore appropriate instrument for coffee or caffeine
consumption for some Mendelian randomization analyses,
given that the other genetic variants are known to be asso-
ciated with other non-caffeine-related phenotypes. How-
ever, it is also important to note that CYP1A2
metabolizes xenobiotic substrates other than caffeine
[28], so SNPs in or near CYP1A1/2 and AHR may have
downstream effects which do not act through caffeine.
Our analysis of the 24-hour dietary recall data allowed
us to explore the speciﬁcity of these associations to subtypes
of tea and coffee as well as other types of beverage con-
sumption. In general, we found consistent evidence for pos-
itive associations between the coffee-related genetic risk
scores and subtypes of coffee (e.g. ﬁlter, latte, espresso),
but associations with tea were limited to standard tea and
did not include other subtypes (rooibos, herbal, green).
There was limited evidence for associations with other
types of beverage (with the exception of water). Given the
variation in consumption of different types of coffee and
tea between countries [29] and by demographic factors
(e.g. age) [4], it is possible that these associations will be
context-speciﬁc. This therefore highlights an important po-
tential source of heterogeneity that may arise between
studies when using these risk scores.
The genetic risk scores associated with both caffeinated
and decaffeinated coffee and tea consumption in UK
Biobank. Associations of AHR variants with decaffeinated
coffee consumption were also reported in the CCGC GWAS
[3]. This is likely to be explained by a continuation of coffee
and tea drinking behaviour in individuals who have
switched from caffeinated to decaffeinated coffee and tea
consumption. However, we did not observe associations
with herbal, green or rooibos tea in UK Biobank; it is possi-
ble that these drinks are not consumed in high enough
quantities or that they are not direct replacements for caf-
feinated beverages. Importantly, it is likely that there is
some misclassiﬁcation of decaffeinated tea and coffee con-
sumption due to the way in which individuals were asked
about decaffeinated drink consumption in UK Biobank
(only being able to say they drank all decaffeinated, all caf-
feinated or a mixture). Therefore, some caution must be
exercised when interpreting these results.
To our knowledge, the negative association between
coffee-related genetic variants and water consumption
Figure 3 Associations between the two single nucleotide polymorphism (SNP) genetic risk scores and caffeinated and decaffeinated coffee. Analyses
restricted to consumers of each drink. Adjusted for age, sex and principal genetic components
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has not been reported previously. The negative association
was also observed for overall non-tea and non-coffee drink
consumption. We think that the most parsimonious expla-
nation for this ﬁnding is that this is a downstream effect of
increased coffee and tea consumption; individuals drinking
more coffee and tea consume fewer other drinks. This is
consistent with ﬂuid homeostasis, whereby the body main-
tains ﬂuid balancewithin a healthy range. Our ﬁndings from
Mendelian randomization analysis also provide some
support for this being a downstream effect of coffee/tea
consumption (i.e. vertical or mediated pleiotropy); MR Egger
and median-weighted regression analysis both provided
some evidence for causal negative effects of coffee consump-
tion on water and total other beverage consumption.
We found some evidence within UK Biobank for
associations with other traits, most notably alcohol con-
sumption. This could be of concern for use of these risk
scores as proxies for coffee or caffeine consumption in
Mendelian randomization studies, as this would potentially
violate the assumption of no horizontal or biological pleiot-
ropy. A previous Mendelian randomization study using
variants in CYP1A1/2 and AHR did not ﬁnd clear
evidence for associations with potential confounders [20],
but did not investigate alcohol consumption. However,
one of the coffee-related variants, rs1260326 (in GCKR),
has been identiﬁed as a novel locus for alcohol consump-
tion in a GWAS conducted in the initial UK Biobank release
[30]. Further work is required to determine whether this
represents a true association and, if so, whether this effect
operates through coffee/tea consumption or through an
independent pathway—the latter would violate the
assumptions of Mendelian randomization. Our ﬁnding that
there was some difference in associations between risk
scores and demographic and life-style factors in groups
with different levels of consumption suggests that stratify-
ing on level of consumption when using these scores could
cause collider stratiﬁcation bias (where selection into a
sample can induce confounding) [31,32].
There are several limitations to this analysis that should
be considered. First, these analyses have been conducted in
individuals of European ancestry and may not be general-
izable to other ethnicities. As discussed above, variation in
type of caffeine consumption by population may also limit
the generalizability of these results. Secondly, the UK
Biobank had a low response rate (approximately 5%),
and is not likely to be representative of individuals of this
age group in the United Kingdom [33]. Thirdly, there is
likely to be measurement error in the reporting of beverage
consumption. In the main questionnaire, individuals could
report consumption of tea and coffee as the exact number
of cups consumed per day, but in the dietary recall study in-
dividuals could only report consumption up to amaximum
of six or more portions per day. Although patterns of
association were very similar for tea and coffee betweenTa
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the two, this restriction of the maximum value is likely to
impact upon the magnitude of associations, particularly
when summing across categories. Therefore, effect sizes
should be interpreted with caution. Fourthly, we were un-
able to speciﬁcally distinguish other forms of caffeinated
beverage consumption in UK Biobank. It is likely that the
carbonated and low-calorie drink categories contain some
caffeine-containing beverages (e.g. cola). Finally, this study
does not assess the association of these risk scores with
blood caffeine levels. As discussed above, variants in or
near CYP1A1/2 and AHRwhich increase coffee consump-
tion decrease plasma caffeine [5,6]. A recent analysis in-
cluding data from UK Biobank has also demonstrated
that the SNPs in GCKR, EFCAB5 and POR also associate
in opposing directions with coffee consumption and
plasma caffeine metabolites [6].
Genetic risk scores for coffee consumption are already
being used as a tool to explore the causal effects of coffee
consumption [20,22] and their use is likely to become
more widespread, given the range of health conditions
with which coffee consumption is associated. We have
demonstrated that genetic risk scores compiled using
variants from coffee consumption GWAS associate more
broadly with caffeine-containing beverages (or decaffein-
ated versions of these beverages). What these variants
relate to within each speciﬁc analysis sample will be
important for interpreting the results of Mendelian ran-
domization analyses. Finally, association of these genetic
risk scores with non-caffeine-related phenotypes, e.g.
alcohol consumption, may invalidate their use to assess
the downstream health effects of caffeine consumption.
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